Abstract: Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

Abstract: A pharmaceutical composition consisting of Radix Polygoni Multiflori extract, Salviae Miltiorrhizae extract, Fructus Crataegi extract and Radix Notoginseng extract is described, wherein the composition optionally contains a pharmaceutical carrier. Processes for producing the composition and methods for treating and/or preventing hyperlipidemia, treating and/or preventing fatty liver and lowering blood lipid level by administration of the pharmaceutical composition are also disclosed.

Abstract: Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

Abstract: The present invention discloses a pharmaceutical composition comprising Polygonum multiflorum Thunb, which comprises Polygonum multiflorum Thunb, Fructus Crataegi, Salvia miltiorrhiza Bunge and Radix Notoginseng. If needed, the pharmaceutical composition may comprise the pharmaceutically acceptable carriers. The weight ratio of Polygonum multiflorum Thunb, Salvia miltiorrhiza Bunge, Fructus Crataegi and Radix Notoginseng in the present composition is as follows: 10 to 20 parts of Polygonum multiflorum Thunb, 5 to 15 parts of Salvia miltiorrhiza Bunge, 10 to 20 parts of Fructus Crataegi and 1 to 10 parts of Radix Notoginseng. Also, the present invention discloses the methods for preparing the composition, including directly pulverizing the medicines into powder to produce the composition or preparing the medicines into the extracts and then make the extracts into drugs.

Abstract: The present invention relates to the matrix adjuvants for drop pills and the preparation of the drop pills. The matrix adjuvants for drop pills of the present invention comprise new matrix adjuvants with or without the plastifying components, which are typically natural matrix adjuvants derived from plants and of safety and non-toxicity. The present invention decreases the toxicity caused by polyethylene glycol, alters the situation that adjuvants derived from animals is scarce, improves the quality of drop pills and accelerates the development of drop pills.